Literature DB >> 32209560

The Frequency of Ras Mutations in Cancer.

Ian A Prior1, Fiona E Hood2, James L Hartley3.   

Abstract

Ras is frequently mutated in cancer, however, there is a lack of consensus in the literature regarding the cancer mutation frequency of Ras, with quoted values varying from 10%-30%. This variability is at least in part due to the selective aggregation of data from different databases and the dominant influence of particular cancer types and particular Ras isoforms within these datasets. To provide a more definitive figure for Ras mutation frequency in cancer, we cross-referenced the data in all major publicly accessible cancer mutation databases to determine reliable mutation frequency values for each Ras isoform in all major cancer types. These percentages were then applied to current U.S. cancer incidence statistics to estimate the number of new patients each year that have Ras-mutant cancers. We find that approximately 19% of patients with cancer harbor Ras mutations, equivalent to approximately 3.4 million new cases per year worldwide. We discuss the Ras isoform and mutation-specific trends evident within the datasets that are relevant to current Ras-targeted therapies. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32209560      PMCID: PMC7367715          DOI: 10.1158/0008-5472.CAN-19-3682

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

1.  Allosteric modulation of Ras-GTP is linked to signal transduction through RAF kinase.

Authors:  Greg Buhrman; V S Senthil Kumar; Murat Cirit; Jason M Haugh; Carla Mattos
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

2.  Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.

Authors:  John C Hunter; Anuj Manandhar; Martin A Carrasco; Deepak Gurbani; Sudershan Gondi; Kenneth D Westover
Journal:  Mol Cancer Res       Date:  2015-06-02       Impact factor: 5.852

3.  Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.

Authors:  Christin E Burd; Wenjin Liu; Minh V Huynh; Meriam A Waqas; James E Gillahan; Kelly S Clark; Kailing Fu; Brit L Martin; William R Jeck; George P Souroullas; David B Darr; Daniel C Zedek; Michael J Miley; Bruce C Baguley; Sharon L Campbell; Norman E Sharpless
Journal:  Cancer Discov       Date:  2014-09-24       Impact factor: 39.397

4.  Farnesyltransferase-Mediated Delivery of a Covalent Inhibitor Overcomes Alternative Prenylation to Mislocalize K-Ras.

Authors:  Chris J Novotny; Gregory L Hamilton; Frank McCormick; Kevan M Shokat
Journal:  ACS Chem Biol       Date:  2017-06-19       Impact factor: 5.100

5.  Profound Tissue Specificity in Proliferation Control Underlies Cancer Drivers and Aneuploidy Patterns.

Authors:  Laura Magill Sack; Teresa Davoli; Mamie Z Li; Yuyang Li; Qikai Xu; Kamila Naxerova; Eric C Wooten; Ronald J Bernardi; Timothy D Martin; Ting Chen; Yumei Leng; Anthony C Liang; Kathleen A Scorsone; Thomas F Westbrook; Kwok-Kin Wong; Stephen J Elledge
Journal:  Cell       Date:  2018-03-22       Impact factor: 41.582

6.  Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.

Authors:  James H Suh; Adrienne Johnson; Lee Albacker; Kai Wang; Juliann Chmielecki; Garrett Frampton; Laurie Gay; Julia A Elvin; Jo-Anne Vergilio; Siraj Ali; Vincent A Miller; Philip J Stephens; Jeffrey S Ross
Journal:  Oncologist       Date:  2016-05-05

7.  Covalent Guanosine Mimetic Inhibitors of G12C KRAS.

Authors:  Yuan Xiong; Jia Lu; John Hunter; Lianbo Li; David Scott; Hwan Geun Choi; Sang Min Lim; Anuj Manandhar; Sudershan Gondi; Taebo Sim; Kenneth D Westover; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2016-11-30       Impact factor: 4.345

8.  Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D.

Authors:  Christian W Johnson; Yi-Jang Lin; Derion Reid; Jillian Parker; Spiro Pavlopoulos; Patrick Dischinger; Carrie Graveel; Andrew J Aguirre; Matthew Steensma; Kevin M Haigis; Carla Mattos
Journal:  Cell Rep       Date:  2019-08-06       Impact factor: 9.423

9.  Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epithelium.

Authors:  Raphael Brandt; Thomas Sell; Mareen Lüthen; Florian Uhlitz; Bertram Klinger; Pamela Riemer; Claudia Giesecke-Thiel; Silvia Schulze; Ismail Amr El-Shimy; Desiree Kunkel; Beatrix Fauler; Thorsten Mielke; Norbert Mages; Bernhard G Herrmann; Christine Sers; Nils Blüthgen; Markus Morkel
Journal:  Nat Commun       Date:  2019-07-02       Impact factor: 14.919

10.  COSMIC: the Catalogue Of Somatic Mutations In Cancer.

Authors:  John G Tate; Sally Bamford; Harry C Jubb; Zbyslaw Sondka; David M Beare; Nidhi Bindal; Harry Boutselakis; Charlotte G Cole; Celestino Creatore; Elisabeth Dawson; Peter Fish; Bhavana Harsha; Charlie Hathaway; Steve C Jupe; Chai Yin Kok; Kate Noble; Laura Ponting; Christopher C Ramshaw; Claire E Rye; Helen E Speedy; Ray Stefancsik; Sam L Thompson; Shicai Wang; Sari Ward; Peter J Campbell; Simon A Forbes
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

View more
  141 in total

1.  Inhibition of RAS: proven and potential vulnerabilities.

Authors:  Mariyam Zuberi; Imran Khan; John P O'Bryan
Journal:  Biochem Soc Trans       Date:  2020-10-30       Impact factor: 5.407

Review 2.  Molecular events in the pathogenesis of vulvar squamous cell carcinoma.

Authors:  Deyin Xing; Oluwole Fadare
Journal:  Semin Diagn Pathol       Date:  2020-09-25       Impact factor: 3.464

3.  Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer.

Authors:  Jonathan M Loree; Yucai Wang; Muddassir A Syed; Alexey V Sorokin; Oluwadara Coker; Joanne Xiu; Benjamin A Weinberg; Ari M Vanderwalde; Anteneh Tesfaye; Victoria M Raymond; Benjamin Miron; Gabi Tarcic; Ori Zelichov; Russell R Broaddus; Patrick Kwok Shing Ng; Kang Jin Jeong; Yiu Huen Tsang; Gordon B Mills; Michael J Overman; Axel Grothey; John L Marshall; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2021-06-11       Impact factor: 12.531

4.  Pulmonary Inflammation and KRAS Mutation in Lung Cancer.

Authors:  Phouthone Keohavong; Y Peter Di
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors.

Authors:  James M Cleary; Victoria Wang; Rebecca S Heist; E Scott Kopetz; Edith P Mitchell; James A Zwiebel; Kevin S Kapner; Helen X Chen; Shuli Li; Robert J Gray; Lisa M McShane; Larry V Rubinstein; David R Patton; Funda Meric-Bernstam; Melissa S Dillmon; P Mickey Williams; Stanley R Hamilton; Barbara A Conley; Andrew J Aguirre; Peter J O'Dwyer; Lyndsay N Harris; Carlos L Arteaga; Alice P Chen; Keith T Flaherty
Journal:  Clin Cancer Res       Date:  2021-02-26       Impact factor: 12.531

Review 6.  An expanded universe of cancer targets.

Authors:  William C Hahn; Joel S Bader; Theodore P Braun; Andrea Califano; Paul A Clemons; Brian J Druker; Andrew J Ewald; Haian Fu; Subhashini Jagu; Christopher J Kemp; William Kim; Calvin J Kuo; Michael McManus; Gordon B Mills; Xiulei Mo; Nidhi Sahni; Stuart L Schreiber; Jessica A Talamas; Pablo Tamayo; Jeffrey W Tyner; Bridget K Wagner; William A Weiss; Daniela S Gerhard
Journal:  Cell       Date:  2021-03-04       Impact factor: 41.582

7.  Monoubiquitination of KRAS at Lysine104 and Lysine147 Modulates Its Dynamics and Interaction with Partner Proteins.

Authors:  Vinay V Nair; Guowei Yin; Jerry Zhang; John F Hancock; Sharon L Campbell; Alemayehu A Gorfe
Journal:  J Phys Chem B       Date:  2021-04-30       Impact factor: 2.991

8.  Malfeasance of KRAS mutations in carcinogenesis.

Authors:  Rupal Tripathi; Shrinidhi Nathany; Anurag Mehta; Ullas Batra; Sakshi Mattoo; Mansi Sharma
Journal:  Clin Exp Med       Date:  2021-03-12       Impact factor: 3.984

Review 9.  RLIP76: A Structural and Functional Triumvirate.

Authors:  Jasmine Cornish; Darerca Owen; Helen R Mott
Journal:  Cancers (Basel)       Date:  2021-05-04       Impact factor: 6.639

Review 10.  Autophagy and tumorigenesis.

Authors:  Michael Rangel; Jerry Kong; Vrushank Bhatt; Khoosheh Khayati; Jessie Yanxiang Guo
Journal:  FEBS J       Date:  2021-07-16       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.